The value of microRNAs as the novel biomarkers for colorectal cancer diagnosis: A meta-analysis |
| |
| Institution: | 1. Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.;2. Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.;3. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.;4. Department of Medical Microbiology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.;5. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.;6. Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.;1. Abbott Cancer Core R&D, Abbott Diagnostics Division, Abbott Park, IL, USA;2. ChemImage Life Sciences, ChemImage Corporation, Pittsburgh, PA, USA;3. Department of Surgical Gastroenterology, Hvidovre Hospital, Denmark |
| |
| Abstract: | BackgroundNumerous studies have reported that microRNAs (miRNAs) hold great potential as the biomarkers for colorectal cancer (CRC). However, inconsistent results have made it challenging to evaluate their diagnostic performance. Thus, the aim of this meta-analysis was to systematically assess the pooled efficacy of miRNAs for CRC diagnosis.MethodsA search for eligible studies up to October 30, 2019 was conducted using PubMed, Web of Science and EMBASE databases. A random-effects model was used to evaluate the pooled sensitivity and specificity. The summary receiver operator characteristic (SROC) curve and area under the curve (AUC) were calculated to assess the overall diagnostic efficacy.ResultsA total of 3258 CRC patients and 2683 healthy controls were identified in 35 included studies. The overall diagnostic accuracy was as follows: sensitivity, 0.80 95 % confidence interval (CI) 0.75?0.83]; specificity, 0.80 (95 % CI, 0.75?0.84); positive likelihood ratio (PLR), 4.0 (95 % CI, 3.2?5.0); negative likelihood ratio (NLR), 0.26 (95 % CI, 0.21?0.31); diagnostic odds ratio (DOR), 16 (95 % CI, 11?23); and AUC, 0.87 (95 % CI, 0.83?0.89).ConclusionThe results indicated that miRNAs, particularly serum-derived miRNAs, can serve as the powerful and promising biomarkers for early CRC screening. |
| |
| Keywords: | Colorectal cancer MicroRNAs Diagnosis Meta-analysis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
